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Mitochondrial dysfunction has long been implicated in progression of cancer. As a paradigm,
the “Warburg effect,” which by means of a switch toward anaerobic metabolism enables
cancer cells to proliferate in oxygen limiting conditions, is well established. Besides this
metabolic transformation of tumors, it has been discovered that mutations in genes encod-
ing mitochondrial proteins are the etiological factors in different types of cancer.This confers
to mitochondrial dysfunction a causative role, rather than resultant, in tumor genesis beyond
its role in tumor progression and development. Mitochondrial proteins encoded by tumor-
suppressor genes are part of the succinate-dehydrogenase, the fumarate-hydratase, and
the mitochondrial isocitrate-dehydrogenase enzymes, all of them participating in the Krebs
cycle. The spectrum of tumors associated with mutations in these genes is becoming
larger and varies between each enzyme. Several mechanisms of tumorigenesis have been
proposed for the different enzymatic defects, most of them based on studies using cellular
and animal models. Regarding the molecular pathways implicated in the oncogenic trans-
formation, one of the first accepted theories was based on the constitutive expression of
the hypoxia-inducible factor 1α (Hif1α) at normal oxygen tension, a theory referred to as
“pseudo-hypoxic drive.” This mechanism has been linked to the three types of mutations,
thus suggesting a central role in cancer. However, other alternative molecular processes,
such as oxidative stress or altered chromatin remodeling, have been also proposed to play
an onco-pathogenic role. In the recent years, the role of oncometabolites, a new concept
emerged from biochemical studies upon these tumors, has acquired relevance as responsi-
ble for tumor formation. Nevertheless, the actual contribution of each of these mechanisms
has not been definitively established. In this review, we summarize the results obtained
from mouse strains genetically modified in the three different enzymes.
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INTRODUCTION
One of the general features of cancer cells is metabolic dereg-
ulation consisting on the production of energy through a high
rate of anaerobic glycolysis in the cytoplasm rather than the mito-
chondrial Krebs cycle/oxidative phosphorylation system, the latter
ultimately depending on oxygen availability. This phenomenon,
described by Otto Warburg decades ago, enables cancer cells to
proliferate in low oxygen conditions (hypoxia) as the tumor grows
larger and oxygen supply becomes limiting. Therefore, the so-
called “Warburg effect” has been largely considered as an adaptive
mechanism rather than a tumor initiation event. However, since
more than one decade ago, a series of mutations in genes encoding
mitochondrial metabolic enzymes has been found to initiate the
oncogenic process.
Mutations in genes encoding three different enzymes of the
Krebs’ cycle have been identified as playing a causative role in sev-
eral types of cancers. These enzymes are succinate dehydrogenase
(SDH) also referred to as the mitochondrial complex II (MCII)
of the electron transport chain (ETC)-, fumarate-hydratase (FH),
and isocitrate dehydrogenase (IDH). Each of them catalyzes one
step of the Krebs cycle, whose major function is to provide NADH
to the mitochondrial ETC and, consequently, to generate ATP. In
addition, some Krebs’ cycle intermediates constitute the starting
point for the biosynthesis of a number of molecules.
The spectrum of tumors caused by mutations in SDH, FH, and
IDH genes differs between them although some overlap exists.
Likewise, different mechanisms have been proposed to account
for the pathological effect of these mutations that share com-
mon pathways. Albeit most of the conclusions have been drawn
from the analysis of human biopsies or, in a more reductionist
approach, from studies in cultured cells, part of the studies have
been conducted in mouse models genetically engineered to harbor
mutations in the orthologous genes. In this review, we summarize
these mouse models and the contribution that they have made to
elucidate the mechanisms that make mutations in mitochondrial
metabolic enzymes to cause cancer.
In the following, we describe the different genetically modified
mouse models generated to date based on the mutations of some
of the genes coding for SDH, FH, and IDH proteins (Table 1). We
also summarize the phenotypes displayed by these mice and the
contribution that they can make toward the understanding of the
mechanisms of tumorigenesis in mitochondria-defective tissues.
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Table 1 | Summary of “knock-out” (KO) and “knock-in” (KI) mouse models.
Gene/s Type of mutant Genotype Phenotypea Reference
SUCCINATE DEHYDROGENASE
SdhD Null KO, homozygous SdhD−/− Embryonic lethal (1)
SdhD Null KO, heterozygous SdhD+/− CB hypertrophy (1)
SdhD/H19 Double null KO, heterozygous SdhD+/− H19+/− CB hypertrophy (2)
SdhD Catecholaminergic tissue-specific
KO (TH-SDHD)
SdhDflox/−; TH-Cre CB and adrenal medulla atrophy,
neurodegeneration, and increased oxidative
damage
(3, 4)
SdhD Conditional inducible KO
(SDHD-ESR)
SdhDflox/−; Cre-ERTM CB and adrenal medulla atrophy, premature
dead, up-regulation of p21WAF/Cip, and partial
“pseudo-hypoxic” response
(3, 5)
SdhB Null KO, homozygous SdhB−/− Embryonic lethal (6)
SdhB Null KO, heterozygous SdhB+/− CB atrophy (6)
SdhB/Bub1 Double null KO, heterozygous SdhB+/− Bub1H/− CB atrophy (6)
SdhB Carrier of “floxed” allele SdhBflox/flox Hypermethylation of DNA and histones in
chromaffin cells in vitro
(7)
SdhC Point mutant, transgenic SdhCV69E Increased ROS levels and oxidative damage
in the mitochondria, mitochondrial respiratory
chain dysfunction, decrease in body size
(8)
FUMARATE HYDRATASE
Fh Null KO, homozygous Fh−/− Embryonic lethal (9)
Fh Renal tissue-specific KO Fhflox/flox; Ksp-Cre Renal cysts, partial “pseudo-hypoxic”
response, up-regulation of p21WAF/Cip, and
up-regulation of antioxidant pathways
(9, 10)
Fh/Hif Renal tissue-specific double KO Fhflox/flox Hif1(2)αflox/flox;
Ksp-Cre
Exacerbated renal cysts (10)
Fh Smooth muscle tissue-specific KO Fhflox/flox; SMC22a-Cre Tumor metabolic profile (11)
ISOCITRATE DEHYDROGENASE
Idh1 Myeloid lineage-specific KI
(LysM-KI)
Lox-STOP-lox-Idh1R132H;
LysM-Cre
Elevated levels of 2-HG, splenomegaly,
extramedullary hematopoiesis,
hypermethylated histones, and changes in
DNA methylation. No “pseudo-hypoxic”
response
(12)
Idh1 Developing neural tissue-specific KI Lox-STOP-lox-Idh1R132H;
Nestin-Cre
Premature death, impaired collagen
synthesis in brain, elevated levels of 2-HG,
and activation of “pseudo-hypoxic” response
(13)
Idh2 Conditional KO inducible by
doxycycline
TRE-Idh2R140Q Elevated levels of 2-HG, extramedullary
hematopoiesis, expansion of HSCs in the
bone marrow, and blockade of the
erythropoiesis
(14)
aMore details in the text.
SUCCINATE DEHYDROGENASE
The SDH (also MCII) enzyme is a multiprotein complex, anchored
to the inner mitochondrial membrane, and composed of four sub-
units: SDHA, B, C, and D. This enzymatic complex has a dual
role: in one side, it carries out the SDH activity in the Krebs
cycle that oxidizes succinate to fumarate in a flavin-dependent
reaction. On the other side, MCII functions in the ETC by transfer-
ring to the ubiquinone Q10 the electrons resulting from succinate
oxidation (15).
The first of these genes found to be responsible of cancer was
SDHD (16), which encodes the small inner membrane-anchoring
protein of the MCII. Indeed,SDHD was the first tumor-suppressor
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gene identified as encoding a mitochondrial protein. Germ-line
mutations on this gene have been found to cause mostly a type of
tumor named hereditary familial paraganglioma type 1, or PGL1
(16, 17). PGL are highly vascularized and slow-growing head and
neck tumor occurring in the paraganglionic system, a diffuse set of
neural crest-derived paraganglia, distributed from the skull base
to the pelvic floor and associated to the major arteries, nerves, and
some organs. The function of the paraganglionic system is to pro-
duce catecholamines during fetal life until the development of the
adrenal medulla, an organ with the same neuroectodermal origin.
In fact, PGL may arise in the adrenal medulla, and then named
adrenal phechromocytoma (PCC), or it may also be extra-adrenal
if it occurs in other abdominal areas. In adults, some paraganglia
retain chemosensitive and neuroendocrine activity, as is the case
for the carotid body (CB), whose major function consists in detect-
ing decreased oxygen levels in the blood (hypoxemia). Soon after
the identification of SDHD, mutations in SDHC and SDHB genes
were found to be responsible for PGL3 and PGL4, respectively
(18, 19). More recently, the long time undiscovered PGL2 com-
plementation group was identified as the SDHDAF2 gene, a factor
required for the assembly of the FAD prosthetic group to MCII
(20). Finally, few somatic or germ-line mutations in the fourth
MCII constituent subunit, SDHA, traditionally linked to neuro-
logical disorders, have been associated to PGL (21, 22). Each of
the PGL groups manifests a different pattern on the type of tumor
(PGL or PCC), location, and malignancy, (23–26). Moreover, for
SDHD and SDHDAF2, a maternally derived imprinting process
accompanied by loss of heterocygocity (LOH) phenomenon seems
to underlie a parent-of-origin effect (16, 17, 27). Although the vast
majority of tumors are PGL and PCC, during the last few years the
spectrum of tumors has broaden, incorporating gastrointestinal
stromal tumor (28, 29), renal carcinoma (30–32), and more rarely,
pituitary tumor (33) and leukemia (34), to the list of different
cancer caused by SDH mutations (25, 28, 35).
The first reported mammalian genetic model lacking a pro-
tein of the ETC consisted of a mouse strain knocked-out (KO)
in the SdhD gene (1). Homozygous SdhD-/- animals die at early
embryonic stages. Heterozygous SdhD+/− mice show a general,
non-compensated deficiency of SDH activity without alterations
in body weight or other major physiological dysfunction. CB
analysis showed subtle glomus cell hypertrophy and hyperpla-
sia. At the functional level, CB glomus cells showed abnormal
enhancement of resting secretory activity due to a decrease of K+
conductance and persistent Ca2+ influx into glomus cells. The
constitutive activation of SdhD+/− glomus cells could precede
CB tumor transformation. However, an increased susceptibility
to generate tumors was not observed, even in aged animals (1).
Similar results were obtained in a second generated SdhD KO
mouse (2). Heterozygous individuals did not show hyperplasia of
PGL-target tissues, such as the CB or the adrenal medulla, nor any
other type of pathology. In an attempt to force the initiation of
tumor development, this strain was crossed with a KO for H19, a
postulated imprinted modifier gene of SdhD – induced tumorige-
nesis. The SdhD/H19 double heterozygous mice showed a trend
to increase the size of the CB. However, no evidence of tumor in
CB or adrenal medulla was obtained during their entire lifespan,
thus confirming the data by Piruat et al. (1).
As loss of the non-mutated allele, i.e., LOH, seems to be a
requirement for the tumor to arise in patients, the lack of develop-
ment of tumors in these SdhD mutant strains could be explained
by biological differences between human and rodents that impair
spontaneous LOH to occur in these mice. Moreover, as the LOH in
PGL1 implicates the loss of the entire chromosome (27), it could
also be possible that other loci needed to prevent the tumor are
still present upon deletion of the SdhD in our model.
Another MCII component KO mouse is the SdhB+/− mouse
strain, which was created by random gene trap integration (6). As
for the mutants in the D subunit, the SdhB-/- homozygous shows
an embryonic lethal phenotype, arresting their development at the
stage of organogenesis. No tumor formation or any abnormalities
were detected in SdhB+/− animals as monitored by abdominal
palpation and weight measurement. In contrast to SdhD mutants,
a trend toward smaller CB size and a reduced number of type I
cells was observed in SdhB+/− heterozygotes (6). No PGL or PCC
tumors were observed in double SdhB+/− SdhD+/−. In an attempt
to enhance LOH rate, a double SdhB+/− Bub1H/- strain was gener-
ated. Bub1 plays a key role in mitotic checkpoint and its deficiency
results in aneuploidy and increased tumorigenesis (36). However,
as observed in single SdhB+/− mice, a tumor phenotype was not
displayed by this double KO.
Since bi-allelic inactivation seems to be a requirement for
tumors to arise and given that the homozygous Sdh mutants cre-
ated previously were embryonic lethal, a conditional KO mouse
carrying a “floxed” SdhD allele (SdhDflox) was generated (3).
This strain was bred with transgenic mouse lines expressing the
site-specific Cre recombinase either tissue-restrictedly or in a
drug-inducible manner. Thus, a tissue-specific mutant in catheco-
laminergic cells was created driving Cre expression by the tyrosine
hydroxylase (TH) promoter [TH-SDHD mouse (3)]. The TH
is the rate-limiting enzyme for cathecolamine synthesis and is
expressed, among other tissues, in type I glomus cells of the CB
and chromaffin cells of the adrenal medulla. TH-SDHD mice are
healthy at birth, and develop normally during the first postna-
tal months. However, they did not show any indication of tumor
transformation in the peripheral catecholaminergic tissues. On
the contrary, quantitative histological analyses of CB and adrenal
medulla showed a marked decrease and degeneration of cate-
cholaminergic cells with abnormal mitochondria and a significant
decrease of intracellular ATP content (3, 4). Some evidence of
oxidative damage was detected in the adrenal medulla of mutant
animals manifested as an increase of lipid peroxidation. Therefore,
although complete deletion of both SdhD alleles was achieved in
these animals, they did not develop tumors. These results strength
the idea that another “hit” is required for PGL/PCC pathogenesis
and that this second event does not take place in the mouse. It could
also be possible that complete maturation of the catecholaminer-
gic organs, a process obliterated in the TH-SDHD model, is a
prerequisite for tumor induction.
A time-inducible SdhD mutant – the so-called SDHD-ESR
mouse – was generated by breeding the mouse line carrying
SdhDflox with a strain containing a tamoxifen-inducible Cre
recombinase (3, 5). Analyses of CB and adrenal medulla in the
SDHD-ESR strain indicated absence of tumorigenesis in these
organs and a clear trend toward degeneration of the CB (3). It
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is noticeable that these animals died 3 weeks after tamoxifen treat-
ment, thus hampering any possibility of further cellular oncogenic
transformation, an event that likely requires a longer period of
time. It had been previously proposed that loss of SdhD leads to
an abnormal activation of the adaptive response to hypoxia medi-
ated by the hypoxia-inducible factors 1 (and 2) alpha (Hif1α and
Hif2α (37)). These transcription factors activate a wide set of genes
involved in processes such as glycolysis and anaerobic metabolism,
hematopoiesis, angiogenesis, and neovascularization (38, 39), all
devoted to increase oxygen availability of tissues. Because of this
function, Hif1α plays a fundamental role in tumor progression.
(40, 41). The analysis of the Hif1α pathway in SDHD-ESR tissues
and in two newly derived cell lines, after complete SdhD loss only
partially recapitulated a “pseudo-hypoxic” response (see below)
and rendered inconsistent results. In order to identify other gene
expression changes elicited by SdhD deletion, microarray analysis
of adrenal medulla and kidney was performed. This study revealed
that each mutant tissue displayed different variations in their
gene expression profiles affecting different biological processes.
Despite these differences, it was found that the Cdkn1a gene was
up-regulated in both tissues (5). This gene encodes the cyclin-
dependent kinase inhibitor p21WAF1/Cip1, a factor implicated in
cell cycle, senescence, and cancer (42, 43). The two SDHD-ESR
cell lines also showed accumulation of this protein. These obser-
vations unveiled a new – although mechanistically unknown – link
between loss of SdhD, p21WAF/Cip activation, and cell proliferation
arrest in a process that could represent a mitochondria-dependent
checkpoint mechanism. It could be speculated that any subsequent
molecular event, i.e., a“third hit”, causing the cell division machin-
ery to by-pass this checkpoint would drive the cells to replicative
catastrophe, accumulating mutations, and eventually resulting in
tumor transformation.
Another conditional “floxed” Sdh-mutant has been reported
for the SdhB subunit (7). In this study, the authors derived and
immortalized chromaffin cells, which were subsequently trans-
fected with Cre-expressing adenoviruses in order to obtain the null
SdhB mutant cells. These cells displayed a general hypermethyla-
tion of DNA and histones. However, conditional SdhB mutant
mice obtained from this animal is not reported and further data
on the in vivo phenotype are not yet available.
Finally, a Tet-mev-1 conditional transgenic mice expressing the
mutated SdhCV69E allele was generated by Ishii et al. (8). This
mouse model is based on the mev-1 mutant of the nematode
Caenorhabditis elegans, which carries a genetic dysfunction of the
homologous SdhC gene (44, 45). The mutation site of SdhCV69E is
located within the functional ubiquinone-binding region of Com-
plex II (44, 46, 47) and was chosen on the basis of its ability to
increase reactive oxygen species (ROS) generation. The Tet-mev-1
mouse had increased ROS levels, mitochondrial oxidative dam-
age,and experienced mitochondrial respiratory chain dysfunction.
Significant decreases in body size and weight were observed dur-
ing neonatal developmental phase. Importantly, no decrease in
SDH activity was detected. Alike the previous MCII KO ani-
mals, no tumor phenotype was displayed by this mouse model,
an expected phenotype considering that the SdhCV69E mutation
does not confer complete lack of MCII function.
FUMARATE HYDRATASE
Mitochondrial FH is a homotetrameric enzyme that catalyzes the
hydration of fumarate to l-malate in the mitochondrial matrix
(48). Heterozygous mutations in the encoding FH gene cause
hereditary leiomyomatosis and renal cell cancer (HLRCC) syn-
drome characterized by multiple cutaneous leiomyomas, benign
smooth muscle tumors of the uterus, aggressive renal cell carcino-
mas, and testicular cancer (49–52). As for SDHD related tumors,
tumor formation in FH heterozygotes is associated with loss of the
second allele (52).
Like mutants in the Sdh genes, Fh1-/- mice died during early
embryogenesis. Hence, a conditional KO mouse carrying a tar-
geted Fh1 “floxed” mutant allele was generated (9). In order to
study specific inactivation of Fh1 in the kidney, the expression of
the Cre recombinase was driven by the Ksp-Cadherin promoter,
which confers tissue-specific expression in the developing kidney.
All mutant animals showed macroscopic proliferative renal cysts
of clonal origin. When the Hif-dependent hypoxia pathway was
analyzed in these cysts, overexpression of Hif1α and Hif2α, as well
as induced expression of some of their target genes (Vegf andGlut1,
but not CA9 and Tgfa), was found. In a more exhaustive analysis
of the global gene expression, a signature was inferred consis-
tent with changes in the Hif pathway, in intermediary (especially
glycolytic) metabolism, and in genes related to cell proliferation.
Interestingly, within this last category, the p21WAF/Cip encoding
gene Cdkn1a was also found up-regulated in Fh-deficient renal
cysts (11). In favor of the pseudo-hypoxic mechanism, other stud-
ies in Fh mutant mouse embryo fibroblasts (MEFs) derived from
Fh1-deficient mice show up-regulation of Hif1α protein as well
as some of its target genes [Hk2, Glut1, and LdhA (11)] mim-
icking what was observed in murine renal cysts. However, in a
subsequent analysis, the same authors showed that mice carrying
the double deletion of Fh1 and Hif1α genes did not suppress the
development of cystic disease, at the contrary, Hif1α deficiency
accelerated and exacerbated cyst formation (10), hence casting
serious doubts on the role of the “pseudo-hypoxia” drive in Fh-
dependent tumorigenesis. In order to find alternative mechanisms,
comparative genome-wide transcript profiling was performed in
Fh deficient kidneys. The obtained results demonstrated that loss
of Fh1 induces expression of NRF2 and up-regulates the NRF2-
mediated antioxidant pathway in a Hif1α independent manner.
Additional studies in MEFs derived from Fh1 mutant demon-
strated that fumarate-mediated succination of cysteine to S-(2-
succinyl)-cysteine residues in KEAP1, a E3-ubiquitin ligase protein
that negative regulates NRF2 (53), abrogated its function (10).
Moreover, a general succination of proteins occurs in Fh-deficient
mice and the same phenomenon has been proposed to be a
robust biomarker of the mutation status in HLRCC patients (54).
Although the multiple renal cysts found in this model resemble
premalignant lesions found in HLRCC patients, regarding the lack
of progression of malignant tumor the authors discuss the possi-
bility that the renal failure observed in these mice could hamper the
progression of dysplasia and subsequent tumor transformation.
Finally, in an attempt to recapitulate the Fh-induced leiomy-
oma, another tissue-specific Fh-deficient mouse strain was gener-
ated. In this case, deletion of the Fh gene in smooth muscle cell
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(SMC) was achieved by driving Cre expression with the SMC22a
promoter (11). The gastrointestinal tract of these mutants showed
no differences in cellular proliferation with respect to control.
Metabolomic analysis of mutant bowels displayed a profile indi-
cating increased cellular fumarate and a progressive up-regulation
of tumorigenic metabolic profile, supported by increased PKM2
and LDHA protein, and reminiscent of the Warburg effect. Unfor-
tunately, as these animals showed a shortened life span and severely
compromised health status, the mouse line was rapidly terminated
thus impairing conclusive results on tumor generation.
ISOCYTRATE DEHYDROGENASE
Isocitrate dehydrogenases are a family of three enzymes (IDH1,
2, and 3) that catalyze the oxidative decarboxylation of isoci-
trate to α-ketoglutarate (α-KG), coupled to reduction of NADP+
to NADPH, which in mitochondria is one of the Krebs’ cycle
reactions. To date, IDH mutations only in the isoforms 1 and
2 – localized in cytoplasm and mitochondria, respectively – are
the cause of tumors in the central nervous system of glial origin
such as astrocytomas, oligodendrogliomas and secondary glioblas-
tomas (55, 56), as well as acute myeloid leukemia [AML (57, 58)]
and other solid tumors (For a review, see (59)).
Therefore, the NADP+-dependant IDH2 is, together with SDH
and FH, the third mitochondrial enzyme found to be mutated in
tumors. However, in this part of the review, we will discuss on
both isoforms of the enzyme, IDH1 and IDH2, as the mecha-
nisms leading to tumorigenesis may well overlap. Importantly,
the mutations found associated to cancer are missense mutations
(IDH1R132, IDH2R140, and IDH2R172) whose residue substitution
takes to a gain-of-function of the enzyme consisting of a neo-
morphic NADPH-dependent activity that converts the normal
product α-KG into the enantiomere 2-hydroxyglutarate [2-HG;
(60, 61)]. This fact impacts strongly on the proposed mechanisms
of tumorigenesis, which will be discussed later.
The first genetically engineered mouse model harboring a
mutation in Idh1 was developed by Sasaki et al. (12). This model
is a conditional knock-in (KI) mouse that expresses the Idh1R132H
mutant allele after Cre-recombinase-mediated excision of a lox-
stop-lox cassette. When crossed with the LysM-Cre mice, the
resulting animal (LysM-KI mouse) expresses the mutant Idh1
specifically in cells of the myeloid lineage. Although LysM-KI mice
were fertile and viable, older animals showed elevated levels of
2-HG, splenomegaly and extramedullary hematopoiesis, together
with an increasing number of hematopietic stem cells (HSCs).
These features, although reminiscent of human myelodysplastic
syndrome, did not evolve AML, a typical progression of the disease
toward the cancerous condition. At the molecular level, LysM-
KI HSCs cells have hypermethylated histones and changes in the
pattern of DNA methylation similar to those observed in human
IDH1- or IDH2-related AML. Moreover, functional analysis of this
epigenetic signature pointed to several signaling pathways involved
in hematopoietic cell proliferation and differentiation and leuke-
mogenesis and leukemic stem cell maintenance. Noteworthy, this
mutant did not show increased levels of Hif1α or induction of
Hif1α-target genes (12).
Interestingly, KO mice homozygous for the null Idh1 gene, i.e.,
with both alleles containing the non-excised lox-stop-lox cassette,
are viable and fertile, whereas mice heterozygous for this allele
and carrying a constitutively expressed Cre are embryonic lethal
at early stages. This observation further supports the notion that
the gain-of-function of the mutant enzyme, leading to production
of 2-HG, rather than inactivation of the enzyme, is what indeed
promotes tumors.
In order to study the effects of the Idh1R132H mutation on
the central nervous system, a mutant strain was generated by
breeding this mutant line with the transgenic Nestin-Cre mice.
In this model, the mutant enzyme is expressed in neuronal and
glial progenitors (13). Animals died shortly after birth due to
cerebral hemorrhage caused by impaired collagen synthesis and
maturation. However, in this model, increased 2-HG inhibited
PHD-mediated degradation of HIF1α, leading to its accumulation
and the induction of HIF-target genes as well.
Other experimental approaches for introducing dominant neg-
ative isoforms of IDH enzymes were based on retroviral transduc-
tion. Thus, as IDH2 mutants develop AML, a mosaic mouse mod-
eling approach for IDH2 mutation was generated by transplanting
sub-lethally irradiated mice with HSCs derived from the dou-
ble KI Flt3-ITD/NrasG12D mutant mice (both mutations being
commonly observed in human AML) and previously transduced
with retroviral factors expressing Idh2 mutant alleles (Idh2R140Q
or Idh2R172K; (57)). Recipient animals displayed reduced survival
compared with recipient animals of control HSCs. The formers
showed leukocytosis, splenomegaly, and high levels of 2-HG. These
results demonstrate that Idh2R140Q or Idh2R172K mutant alleles
observed in human cancers can act as potent oncogenes in mice,
but this action is performed in a cooperative manner together with
Flt3-ITD and NrasG12D mutations to promote AML.
Recently, the generation and hematological characterization
of a transgenic mouse with doxycycline-induced expression of
the mutant Idh2R140Q allele has been reported (14). Although
the expression of mutant Idh2R140Q resulted in alterations within
the hematopoietic compartment characterized by extramedullary
hematopoiesis in the spleen, expansion of HSCs within the bone
marrow, and blockade of the erythropoiesis, it was not suffi-
cient to induce leukemogenesis in the mice. However, retroviral
overexpression in HSCs of the homeobox proteins HoxA9 and
Meis1a (downstream players in numerous pathways found dereg-
ulated AML) or double Idh2R140Q/Flt3-ITD transgenic animals
did recapitulate AML features, strengthening the conclusion that
Idh2 mutations require additional genetic events to cause leukemic
transformation.
MECHANISMS OF TUMOR GENESIS IN MITOCHONDRIAL
DEFICIENT TISSUES
As stated, mutations in these three different but biochemically
related mitochondrial proteins lead to different tumor types.
Mechanistically, an energetic/biosynthetic collapse of the mito-
chondria could be invoked as responsible for the tumoral trans-
formation. However, it would be a rather simplistic view of the
problem, as this general failure would not explain the tissue speci-
ficity or the different features for each type of cancer. Moreover,
most of mutations that compromise the ETC – and therefore ATP
synthesis – lead to a big plethora of degenerative diseases, affect-
ing several systems in the organism, rather than hyperproliferative
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syndromes (62). Therefore, the question remains: What is the
mechanism by which mutations in these mitochondrial proteins
give rise to cancer?
A relatively big amount of results has been published pointing
to activation of common pathways upon mutation of mitochondr-
ial tumor-suppressor genes. One of the first proposed hypotheses
consisted on that dysfunction of one of the three enzymes leads
to an abnormal activation of the adaptive response to hypoxia.
The most versatile system of chronic response to hypoxia is medi-
ated by Hif proteins. In most higher eukaryotes, hypoxia induces
the expression of a wide set of genes involved in processes that
increase the availability of oxygen to tissues and optimize its usage
for energy production (38, 39). These genes are activated by Hif1α
(or Hif2α), which is constantly degraded by the proteosome when
oxygen levels are in the normal range (63). The signal that leads
to Hif1α degradation is its hydroxylation by a family of cytoso-
lic prolyl-hydroxilases (PHDs) that utilize oxygen, iron, and α-KG
as cofactors. When oxygen levels decrease becoming limiting for
the PHDs, Hif1α is not hydroxylated, which allows its stabilization
and nuclear translocation (64, 65). Because of its capability for
increasing oxygen availability in tissues, Hif1α plays a fundamen-
tal role in tumor progression. In this regard, it is well established
that processes such as angiogenesis and glycolysis are regulated, at
least in part, by Hif1α (40, 41).
Several studies suggest this common unity of action of muta-
tions in SDH, FH, and IDH that implicate stabilization of Hif1α
under normal oxygen tension, a situation termed to as “pseudo-
hypoxia” (66). The SDH substrate succinate, which accumulates
in SDH-deficient cells, is one of the products resulting from
Hif1α hydroxylation and has the ability to inhibit the α-KG-
dependent PHDs (37). Likewise, structural, biochemical, and bio-
logical analyses have established that fumarate, which accumulates
in FH-defective cells, also binds PHDs and inhibits their activity
(67–69). This metabolite-induced PHD inhibition is supposed to
up-regulate Hif-dependent transcriptional pathways, as it occurs
in hypoxia (69). Indeed, Hif1α and Hif2α protein levels, as well
as the expression of several Hif-target genes, are increased upon
genetic or pharmacological inhibition of SDH or FH (11, 68, 70).
In the case of IDH deficient cells, a decrease in the level of the pro-
duced α-KG due to lack of enzymatic activity would also result in
inhibition of PHDs (71). In favor of the“pseudo-hypoxia”hypoth-
esis for tumorigenesis, a large amount of data exists showing
activation of the hypoxia response in human tumors carrying these
mutations (24, 72, 73). Furthermore, there seems to be a direct cor-
relation between the expression level of Hif-regulated genes within
the neoplastic tissue and the degree of tumor aggressiveness. Con-
sequently, the constitutive activation of angiogenesis, anaerobic
metabolism, and cell proliferation pathways would facilitate tumor
development at the early stages.
However, whether this phenotype is a consequence of the
tumor hypoxic environment or plays a causative role is under
debate. Regarding the genetic mouse models presented here the
results obtained do not point to a general and consistent “pseudo-
hypoxic” drive. For instance, activation of the Hif1α mediated
hypoxic response takes place upon loss of SDH in MEFs (5), of
FH in MEFs and renal cysts (11), and upon neuronal expression
of the Idh1R132H mutation (13). Increased levels of fumarate in
Fh-deficient renal cell carcinomas causes stabilization of Hif2α
and induces cell motility and tumor invasiveness (76). How-
ever, a general induction of the “pseudo-hypoxia drive” cannot
be concluded since it does not happen in other tissues of these
mutants. Thus, gene expression analysis of two SdhD-/- tissues did
not show activation of Hif-dependent genes or accumulation of
Hif proteins (5). Ablation of Hif1α in a Fh mutant background
exacerbated cyst formation (10), an opposite phenotype to that
expected if the premalignant lesions were consequences of Hif1α
induction. Finally, thorough analysis of a myeloid cell, lineage-
specific Idh1 did not show increased levels of Hif1α or induction
of Hif1α-target genes (12).
Although the molecular mechanisms of tumorigenesis upon
dysfunction of mitochondrial enzymes seem to converge on the
hypoxia adaptive response at least partially, there might be other
pathways involved. For instance, several groups have proposed that
in SDH-deficient cultured cells an increase in the levels of ROS
occurs likely due to electron leakage from the MCII and/or perhaps
a biased accumulation of the semi reduced form of ubiquinone
(74, 75). Concordantly, a number of experiments have allowed
to detect oxidative damage of lipids in the AM of tissue-specific
SdhD mutants (3), increased ROS levels and oxidative damage in
the mitochondria of mouse SdhC mutants (8), and activation of
the antioxidant system in FH mutant (10). It is proposed that free
radicals generated in these conditions could contribute to tumori-
genesis in a Hif-independent manner,by causing DNA damage and
leading eventually to mutations in tumor-suppressor genes and
proto-oncogenes (44). Similar to SDH mutants, a tumor-derived
cell line carrying mutations in FH display constitutively elevated
ROS levels (76). Although oxidative damage should not be under-
estimated since it has important consequences for the cell and may
contribute to the tumor phenotype, whether free radicals are the
etiopathogenic agents is far from being definitively established.
An alternative model is based on evidences that accumulated
succinate and/or fumarate may inhibit other members of the
broad α-KG-dependent dioxygenase family. This includes, among
others, JmjC-containing histone demethylases (JHDMs), collagen
prolyl-4-hydroxylases, and the TET family of 5-methlycytosine
DNA methylases (77). Succinate has proven to affect histone
methylation in yeast (78) and mammalian cells (79). Moreover,
both fumarate and succinate accumulations cause DNA and his-
tone hypermethylation and transcriptional silencing of tumor-
suppressor genes, succinate being more potent than fumarate (80).
This global epigenetic dysregulation could have a broad impact on
gene expression, which may underlie the tumorigenic role of FH
and SDH mutations. Recently, it has been reported that complete
deletion of SdhB protein in mouse chromaffin cells led to succi-
nate accumulation and increased methylated histones due to the
inhibition of α-KG-dependent histone and DNA demethylases (7).
Nevertheless, the most robust evidence for a mechanism of action
based on histone and DNA epigenetic modification comes from
mutants in IDH. The IDH mutations found in patients confer a
gain-of-function rather than inactivation of the enzyme. To date,
the IDH mutations identified in tumors lead to the substitution
of arginine residues located in the active site and conserved in
the three isoforms. As a result, the mutant forms of the proteins
acquire a neomorphic NADPH-consuming activity that converts
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the normal product α-KG into 2-hydroxyglutarate [2-HG (60,
61)], which in turn has the ability to competitively inhibit a large
number of α-KG-dependent dioxygenases. Among them are DNA
methyl-transferases and histone demethylases (81, 82). A poten-
tial inhibition of PHDs leading to Hif1α accumulation has not
been demonstrated. Quite the opposite, 2-HG is able to acti-
vate PHD2 by prior non-enzymatic oxidation to α-KG (83, 84).
Finally, there are recent evidences suggesting that 2-HG could also
inhibit the mitochondrial complex V through extending lifespan
and age-related diseases in the worn Caenorhabditis elegans (85).
In sum, not only α-KG, but succinate and fumarate also could
play a role as “oncometabolites,” a term coined to emphasize the
oncogenic role of certain metabolites under certain circumstances
and through a mechanism implicating epigenetic regulation of the
gene expression.
CONCLUSION
Cell cultures constitute appropriated in vivo models for mecha-
nistic studies of the molecular responses to gene inactivation that
may lead tumor transformation. However, they lack the systemic
environment in which the tumor arises and grows. In the other
hand, results obtained from human biopsies are subjected to mis-
interpretation, since the experiments are performed with samples
in an end-point situation, where many compensatory phenomena
may have happened. Moreover, as the tumor has already devel-
oped, many of the observations may be consequences of tumor
development rather than causative events.
For these reasons, engineering mouse models with the same, or
similar, genetic abnormalities as observed in patients constitute in
principle ideal biological models that mimic tumor syndromes,
allow the study of the mechanisms of tumorigenesis in a sys-
temic context, and have the potential of being used as biological
pre-clinical systems for drug testing. However, the actual limita-
tion of the genetic murine models with mutations in SDH, FH,
and IDH enzymes generated to date (Table 1) is that they do
not develop tumors in any case, being the renal cyst formation
of kidney-specific FH mutant be the most reliable phenotype of
uncontrolled cell proliferation. The reasons for this lack of tumor
phenotype can be different for each model. It is evident that the
genomic organization of mice and human are different. This may
underlie the differences in the tumorigenic response to gene dele-
tion. For instance, in the case of PGL caused by mutations in
SDHD, it has been reported that the complete loss of the chromo-
some where the gene is located occurs (27). Concomitant loss
of other genes in the same chromosome, which in mouse are
located in different chromosomes, could be a required event to
initiate the tumoral process. Similar phenomena could underlie
the lack of tumor phenotype in the rest of mouse models reviewed
here. Despite the failure in tumor arousal of the models reviewed
here, their molecular, genetic, epigenetic, and metabolic analy-
ses will make important contributions to the field. For instance,
large-scale analysis of gene expression in SDH (5) and FH (11)
mutant tissues has demonstrated altered expression of a number
of genes involved in a number of cellular processes. These types
of analyses together with other high throughput technologies,
such as epigenomic and proteomic will surely contribute to deci-
pher additional and/or alternative mechanisms of mitochondrial
defective-induced tumorigenesis.
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